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Abstract
Background: This study aimed to determine the ability of multimodal evaluation with multiparametric 3T-MRI
(MPMRI) and positron emission tomography - computed tomography (PET/CT) to detect cancer of unknown
primary origin (CUP) with neck lymph node (LN) metastasis.
Methods: The study group comprised 38 retrospectively analysed consecutive patients with LN metastasis in the
head and neck (HN) region without known primary tumours (PTs). Statistical values of 3T-MRI and of FDG-PET/CT
scans were evaluated.
Results: Of the 38 CUPs, conventional native T1-, T2-weighted and STIR sequences detected 6 PTs. Native
sequences plus diffusion-weighted imaging (DWI) found 14-, and with fat suppression contrast-enhanced T1-
weighted measurement as well as with the complex MPMRI found 15 primaries and with PET/CT 17 CUPs could be
evaluated, respectively. The detection rates were 15.8, 36.8, 39.5, 39.5 and 44.7 % for conventional native MRI, native
plus DWI, native with contrast-enhanced MRI (CE-MRI), for MPMRI, and for PET/CT, respectively. The overall
detection rate proved by histology was 47.4 %. PET/CT provided the highest sensitivity (Sv: 94.4 %) but a lower
specificity (Sp: 65.0 %), using MPMRI (Sv: 88.2 %) the specificity increased to 71.4 %. DWIincreased specificity of the
native sequences (Sp: 76.2 %). Conventional native sequences plus DWI as well as 3T-MPMRI and PET/CT were same
accurate (Acc: 79.0 %) and had similar likelihood ratio (LR: 3.42, 3.03 and 2.62) in detecting unknown PT sites.
Conclusions: The accuracy of FDG-PET/CT and MPMRI in case of CUP in finding the primary cancer in the neck
regions is identical. While using PET/CT whole body information can be obtained in one examination. MPMRI
shows the local soft tissue status more accurately. In cases of CUP PET/CT should be the first method of choice if it
is available. MPMRI can clarify the exact primary tumor stage, and it can be advantageous in clarifying the
prognostic factors, which is necessary in case of advanced tumor stage and when surgery is under consideration. In
case low N stage is likely after the clinical examination and wait and see policy can be considered, MPMRI is
recommended, and in this case the significance the of radiation free MPMRI is increasing.
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Background
According to the European Society for Medical Oncology
(ESMO) guidelines, cancers of unknown primary origin
(CUP) represent a heterogeneous group of metastatic
tumours for which a standardised diagnostic work-up fails
to identify the site of origin at the time of diagnosis. The
term CUP is reserved for epithelial malignancies because
other types of malignancies (such as melanomas, sarco-
mas, lymphomas) can usually be easily identified using im-
munohistochemistry [1, 2]. CUPs account for 3–5 % of all
malignancies [3, 4] and in 24–36 % of patients with CUPs,
the metastatic lymph node (LN) manifestations of the un-
known primary cancer are in the head and neck (HN) re-
gion [5]. The primary tumour (PT) site in these patients is
eventually identified in only 20–40 % of cases [6].
In general, the prognosis of CUP is poor, and the me-
dian survival time for such patients is 6–10 months. In
cases of CUP in the HN, the outcome is more
favourable, with 5-year survival ranging from 35 to 50 %;
this is especially true in cases with detected PTs because
targeted therapy is possible (PT surgery, radiation
focused to the tumour) [7].
The majority of cancers in the HN are squamous cell
carcinomas (SCC), followed by adenocarcinoma, undif-
ferentiated carcinoma, and adenoid cystic carcinoma.
The location corresponding to the cytological result of
metastatic LNs may provide an indication of the site of
the PT. Finding, localising, and staging the PT and the
cervical nodal metastasis play key roles in treatment
planning [8].
For the accurate diagnosis of CUP, physical examin-
ation, fibre-optic laryngoscopy, and nasopharyngoscopy
are applied, although the majority of suspected primary
sites are detected by radiographic workup.
PET combined with CT (PET/CT) scanning improves
the detection of occult cervical lymphatic disease and
assists in the localisation of unknown PT and distant
metastases [9]. A meta-analysis of 16 studies (published
in 2004) found that FDG-PET or PET/CT detected 74
PTs (24.5 %) in 302 CUP patients with neck node metas-
tases; the overall sensitivity was 88.3 %, specificity
74.9 %, and accuracy 78.8 % [10]. Moreover, FDG-PET/
CT has lower specificity than sensitivity and is more
useful for detecting distant metastases and synchronous
tumour than LN metastasis [11, 12].
Functional and molecular information can also be ob-
tained using magnetic resonance imaging (MRI), as
diffusion-weighted MRI (DW-MRI) is able to character-
ise the tissue based on differences in tissue water mobil-
ity. In a recently published paper, it was concluded that
analysis using diffusion-weighted imaging (DWI) could
be very useful to differentiate malignant and benign
lesions in the HN region [13, 14]. The ADC is a quanti-
tative biomarker of the extent of diffusion restriction,
measured in 10−3 mm2/s units, although no common
threshold ADC value exists in clinical routine to differ-
entiate between malignant and benign tissue [15–17].
The first significant paper showing the usefulness of
DWI in HN tumours was published in 2001. Wang et al.
used an ADC value threshold of 1.22×10−3 mm2/s to dif-
ferentiate benign from malignant tissue, and this value
demonstrated 86 % accuracy, 84 % sensitivity and 91 %
specificity for predicting malignancy [18].
By performing a retrospective analysis, we sought to
evaluate new imaging methods in the management of
occult tumours. In particular, we compared the ability of
positron emission tomography - computed tomography
(PET/CT) and 3-Tesla (3T) multiparametric magnetic
resonance imaging (MPMRI), using high-resolution ana-
tomic and functional DWI, to detect tumours in our
CUP patient population with cervical node metastasis.
Methods
We retrospectively reviewed the medical records of all
patients with a diagnosis of neck LN metastasis of CUP,
who underwent 3T MPMRI with conventional as well as
DWI and whole-body fluoro-2-deoxy-D-glucose (FDG)-
PET/CT examinations between July 01, 2012 and May
15, 2016. Thirty eight patients (24 male, 14 female, mean
age 63 years) fulfilled the following inclusion criteria: 1)
the diagnosis of metastatic LN in the neck was con-
firmed with fine needle aspiration biopsy (FNAB) and 2)
3T MPMRI and FDG-PET/CT imaging were performed
within 6 weeks prior to treatment except for two
patients who had 7 and 8 weeks before treatment. All pa-
tients were first evaluated with complete head and neck
physical examinations performed by HN specialists. All
patients had carcinoma proven by cytology after FNAB
from a cervical LN metastasis before PET/CT and MRI.
For this study, 2 radiologists and nuclear medicine phy-
sicians specialised in HN imaging evaluated the MPMRI
and PET/CT images retrospectively. Clinical findings were
used to evaluate the performance of both methods. The
two experienced interpreters evaluating MPMRI data sets
were in consensus, FDG-PET/CT interpreters were also in
consensus. One of the MPMRI interpreters has 20 years
of experience in the head and neck tumor cases, the other
one has 10 years of experience. One of the FDG-PET/CT
interpreters has 10 years of experience in the field of head
and neck cases, the other one has 6 years of experience.
The evaluating interpreters were blinded to the other im-
aging modality. Postgraduate courses are frequently held
in head and neck radiology in our institute, with constant
consulting with the PET/CT center. The observers
reviewed all visible LNs and the possible PT sites in all 38
patients. We considered tumour-positive imaging results
as true positives when the second clinical examination
with panendoscopy and biopsy revealed the PT.
Gődény et al. Cancer Imaging  (2016) 16:38 Page 2 of 11
MPMRI was performed using a 3T wide-bore MR
scanner (General Electric Discovery 750w, Milwaukee,
WI) using a high-resolution HN surface coil. We opti-
mised our MR techniques to increase spatial resolution
and maintain an adequate signal to noise ratio (SNR),
and the scan time was minimised to avoid motion arte-
facts. T1W and STIR axial and T1W coronal sequences
were applied to the whole neck extended the latest till
tracheal bifurcation using also axial T1W slices to the
upper mediastinum. We applied a field of view (FOV) of
240 × 240 mm in axial and 280–320 mm in coronal, slice
thickness of 5 mm, 0.5–1 mm interslice gap, and 288 ×
256, 320 × 288 matrix size with nex2. T2W turbo spin
echo and DW echo-planar axial images were obtained to
the regions of suspected PT with FOV 240 × 240, slice
thickness/gap of 3.6/0.3 mm. The DW sequence was
performed as part of our routine examination before the
contrast-enhanced T1-weighted with fat suppression
(CET1WFS). A 2D spin-echo DW echo-planar STIR im-
aging sequence (TR 6130/TE minimum, 65–70 ms, in-
version time 200 ms) was used an acquisition matrix of
112 × 80 or 64 × 84, numbers of acquisition of 3, 6, 12
depending on the “b” values. Quantification was per-
formed using an apparent diffusion coefficient (ADC).
To reduce the influence of the perfusion effect on the
ADC calculation, we applied higher b-values (50, 500,
and 1,000 s/mm2). Regions of interest (ROIs) were
placed in the typical soft tissue signal intensity parts of
the measurable lesion, which showed high signal inten-
sity on the b = 50 and b = 1,000 images and low signal
intensity on the ADC map.
After the administration of an intravenous
gadolinium-based contrast agent, we obtained T1W,
fast-spoiled gradient echo sequences with fat suppres-
sion (CET1WFS) for axial, coronal, and sagittal images.
We applied a 260 × 260 mm FOV, 320 × 320 matrix, and
2 mm slice thickness; in addition, a 3 mm slice thickness
was reconstructed in all three planes. The injection rate
was 2 ml/s (using a power injector), with a dosage of
0.1 mmol/kg body weight gadobenate dimeglumine
(Multihance, Bracco, Italy). The MPMRI examination
lasted for 30 min.
FDG-PET-CT scans were performed after at least 6 h
of fasting and were carried out in compliance with the
standard whole-body protocol using a Biograph 6 HD
type camera (Siemens, Knoxville, TN). The injected 18F-
FDG had radioactivity in the range of 3.7 to 5.5 MBq/kg.
The time from FDG injection to PET data acquisition
was between 55 and 120 min. In each case, patients were
tested for blood sugar level using blood taken from the
fingertip before administering the FDG. For patients
with glucose level higher than 7 mmol/l (126 mg/dl), the
scan was rescheduled. PET/CT scanning took place from
the skull base to the upper third of the thighs. Non-
enhanced, low-dose (110/70 kV/mAs) CT was performed
for all patients. PET data acquisition lasted for 3 min for
each bed position. Attenuation-corrected and non-
corrected images were reconstructed with the help of the
CT data using a 3D iterative algorithm. A manufacturer-
specific implementation of the point spread function
(PSF) correction method (True-X) was also applied during
reconstruction, which helped to recover the activity con-
centration of smaller lesions as well as provide uniform
spatial resolution throughout the FOV. The degree of sus-
picion of malignant involvement was based on qualitative
visual interpretation of the images, and no quantitative
analysis, such as the measurement of standardised uptake
values, was performed.
The imaging data of the MRI and PET/CT examina-
tions of the patients were compared to the pathological
findings. Based on the 2nd edition of the Medical statis-
tics, the sensitivity, specificity, positive predictive value,
accuracy and “Likelihood Ratio” (LR) of the examina-
tions were calculated [19].
Results
Thirty eight patients were examined using both PET/CT
and wide-bore 3T MPMRI. Twenty four (63 %) patients
were male, and 14 (37 %) were female. The mean age of
the study group was 63 years, with a range between 24
and 78 years. All patients had carcinoma proven by
cytology after FNAB from a cervical LN metastasis
before PET/CT and MRI.
Possible PT sites were indicated by PET/CT in 24 patients
and by MPMRI in 21 cases. Of these patients, 17 PET-CT
and 15 MRI examinations confirmed histologically malig-
nant tumours (Table 1 shows the sites of the PTs, Figs. 1
and 2). The detection rate of conventional native MRI was
15.8 %, of conventional native sequences plus DWI 36.8 %,
of conventional native sequences with CET1WFS 39.5 %, of
MPMRI 39.5 %, and of PET/CT 44.7 %.
In the complex diagnostic evaluation procedure (im-
aging + panendoscopy + biopsy), a total of 18 patients (de-
tection rate 47.4 %) received histologically confirmed PT
diagnoses. Table 2 and Fig. 3 show the statistical values.
The PT stage determined in the neck based on imaging
was T3 only in 1 case of a sub-mucous cancer in the
mesopharynx. T2 in 5cases and in the other 9 neck cases,
the tumour was classified as T1. The lung and the breast
cancers were T2 and the colon cancer was T3 stage.
The histologically proven tumours typically demon-
strated high signal intensity on high-b-value DWIs with
decreased signal intensity on the ADC (Fig. 4), as well as
high signal intensity on the e-ADC map (Fig. 2). The
median ADC value was found to be 0.892 × 10−3mm2/s
for the neck PTs. Table 3 shows the ADC values, stage
and histology of the histologically proven occult PTs
with cervical node metastasis in the head and neck.
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In a histologically proven case of inflammatory disease,
all MR measurements were false positives for tumour of
the base of tongue, except for the DWI, with an ADC
value of 2.100 × 10−3mm2/s (Fig. 5). In 3 base of tongue
cases all MR sequences were false positive, DWI demon-
strated by the high signal intensity on high-b-value, de-
creased signal intensity on the ADC map, and resulted
0.928, 0.741, 1.13 × 10−3mm2/s ADC values.
In 5 cases the PT sites could not be evaluated on DWI
secondary to the reduced information because of suscep-
tibility artefacts.
Nodal (N) staging was also carried out, and both
methods were positive for cervical LN metastases in
every patient. The upper and middle cervical LNs were
the most frequently involved nodal levels.
Two patients, metachronous metastases were found
with PET/CT, one poorly differentiated SCC manifesta-
tions in the lung and in the bone, and lung metastases
were detected in the hemangiosarcoma case.
Thirty two patients received radiotherapy, 26 com-
bined with chemotherapy (Table 4).
For radiation therapies planning both modalities were
effectively applicable. Patients were immobilized with a
thermoplastic mask and treated with 3-dimensional (3D)
conformal treatment or intensity-modulated radiation
therapy (IMRT) using 6 MV photons. The planned
Table 1 Localisation of detected CUP with LN metastasis in the
neck region
Tumour sites MPMRI PET-CT Histology
T+ F- F+ T+ F- F+
Nasopharynx 3 3 1 3
Mesopharynx 2 2 2
Palatine tonsil 2 1 2 1 2
Base of tongue 3 3 2 5 3
Glandula submand. 1
Hypopharynx 2 2 2
Supraglottic larynx 1 1 1 1
Parotis 1 1 1
Thyroid 1 1
Neck soft tissue 1 1 1
Lung 1 1 1
Breast 1 1 1
Colon - sigma 1 1
SUMMARY 15 2 6 17 1 7 18
T+ true positive, F- false negative, F+ false positive
Fig. 1 Images collected from a 64-year-old male with T1 nasopharyngeal carcinoma and bilateral metastatic nodes. Axial contrast-enhanced T1-
weighted fat suppression (CET1WFS) image (a) shows a small enhancing lesion in the left side of the nasopharynx (arrows). Coronal T1W image
(b) shows bilateral LN involvement. Bilateral diffusion restriction with signal increase can be seen in the axial trace DW images (c and d, b-value:
1,000 s/mm2, ADC: left 0.772, right 0.758 ×10−3mm2/s in the PT and 0.991 ×10−3mm2/s median ADC value was found in the LNs). Increased uptake
corresponding to the occult primary tumour (arrow) can be seen on the sagittal PET/CT fusion image (e) of metastatic nodes (lower arrow) as well as
on the axial FDG-PET scan (f). SCC of nasopharynx, stage T1N2M0
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radiation dose to the primary tumor and the involved
lymph nodes was 66–70 Gy in definitive radiotherapy.
For chemoradiotherapy, 100 mg/m2 cisplatin was admin-
istered two or three times (on the 1st, 22ndand 43rddays
of radiotherapy).
One patient with N1 CUP after selective neck dissec-
tion (SND) was followed by clinical examination and im-
aging and did not receive any other therapy. Nineteen
patients underwent neck dissection (ND), 14 radical ND
(RND), 1selective ND (SND) and 4 modified ND (MND).
Fig. 2 Images of a 56-year-old male with a large right-sided LN metastasis of a small SCC in the right piriform recess. T2W-STIR (a) and CET1WFS
(b) show small soft tissue swelling in the entrance of the right piriform recess; ipsilateral kolliquated LNs can be observed. Findings also revealed
substantial diffusion restriction with signal increase in axial trace DW images (c and d, b-value: 1,000 s/mm2) and a corresponding signal decrease
in the ADC map (e) and a signal increase in the e-ADC image (f). Note the ADC values, which measured 0.790 × 10−3 mm2/s in the PT and 0.740
× 10−3 mm2/s in the LN. On the axial PET-CT fusion image (g) and on the FDG-PET scan (h), increased uptake corresponding to the occult PT
(arrow) and metastatic nodes can be seen. SCC of hypopharynx, stage T1N3M0
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Discussion
Detection of the PT has a large impact on the prognosis
of CUP patients with metastatic LNs in the neck. As in
most cancers, the prognosis mainly depends upon the
stage of the tumour and the applied therapy [20]. Super-
ior characterisation of soft tissues and better visualisa-
tion of tumour extent can be of benefit both in surgical
and radiotherapy planning by improving the assessment
of planning margins for dose escalation [21, 22].
The location of metastatic LNs may indicate the loca-
tion of the unknown PT. When LNs of the upper and
middle cervical level are involved, the primary site of the
tumour is more likely located in the HN region. If lower
cervical levels are involved, the PT is often located below
the clavicles. In patients in whom histopathology has
shown SCC, the primary site is often located in the pal-
atine tonsils or in areas difficult to inspect, such as the
piriform sinus or the nasopharynx [23, 24]. Lapeyre et
al. reported on 87 patients with nodal neck metastasis
and an unknown primary site who were evaluated
between 1969 and 1992 and underwent a unilateral ton-
sillectomy; 26 % of these patients were found to have
tonsillar cancer [25]. In our patients the number of cases
of histologically proven palatine tonsil carcinoma was
only 2 (5.3 %).
The sites of distant metastasis (M) in most HN cancer
(HNC) cases are the lung and the bone (and rarely the
liver and brain). The risk of distant metastasis is more
dependent on the “N” than on the “T” status [8, 26]. In
our study we found 3 patients with synchronous distant
metastases using PET/CT. In 1 unknown primary
tumour with N3 stage patient occult bone metastasis
was detected. In case of colon PT synchronous bone-,
lung- and liver metastases were found. In the triple
negative breast cancer patient multiple manifestations
were found in the thorax wall and in the abdomen.
In the management of CUP patients, clinical examin-
ation with panendoscopy is the basic method, although
the majority of suspected primary sites are detected by
imaging workup. MRI is considered superior to CT for
Table 2 Statistical values of 3T-MPMRI and FDG-PET/CT scans in the evaluation of CUP
Detection rate % T+/38 T+ F- Sv % T- F+ Sp % PPV ACC % LR
MRI native: T1, T2, STIR 15.8 6 11 35.3 13 8 61.9 0.43 50.0 0.92
DWI 34.2 13 2 + 5a 65.0 14 4 77.8 0.76 71.1 2.95
MRI native sequences + DWI 36.8 14 3 82.4 16 5 76.2 0.74 79.0 3.42
MRI native + CE-T1FS 39.5 15 2 88.2 12 9 57.1 0.63 71.1 2.05
MPMRI 39.5 15 2 88.2 15 6 71.4 0.71 79.0 3.03
PET-CT 44.7 17 1 94.4 13 7 65.0 0.71 79.0 2.69
Overall proved by histology 47.4 18
T+ true positive, F- false negative, T-: true negative, F+ false positive, Sv sensitivity, Sp specificity, PPV positive predictive value, LR Likelihood Ratio
ain 5 cases reduced imaging information because of susceptibility artifacts
Fig. 3 Statistical values of 3T MPMRI and FDG-PET/CT scans in the evaluation of CUP with LN metastasis in the neck region
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Fig. 4 Images obtained from a 77-year-old male illustrate false negative conventional native MRI (a T2W-STIR). True positive findings showing a
small signal enhancement with contrast (b CET1WFS), increase with diffusion restriction can be seen in the axial original DW image (c, d, b-value:
1,000 s/mm2) and the corresponding signal decrease in the ADC map (e), which measured 0.773 × 10−3 mm2/s in the PT and 0.771 × 10−3 mm2/s in
the LN. SCC of mesopharynx, stage T1N2bM0




1. Nasopharynx 0.760 cT2 cN3b Poorly differentiated SCC
2. Nasopharynx 0.798 cT1 cN2 Nasopharyngeal carcinoma-EBV associated
3. Nasopharynx 0.772 cT2 cN3b Poorly differentiated SCC
4. Mesopharynx 1.150 cT1 cN2b Poorly differentiated SCC
5. Mesopharynx artefacts cT1 pN2b Poorly differentiated SCC
6. Base of tongue 0.773 cT1 pN2a Well differentiated SCC
7. Base of tongue 1.20 cT2 pN2b Moderately differentiated SCC
8. Base of tongue 0.816 cT2 pN2a Poorly differentiated SCC - HPV associated
9. Palatine tonsil 0.821 pT1 pN2b Poorly differentiated SCC
10. Palatine tonsil 0.702 cT3 cN2b Moderately differentiated carcinoma planocellulare
11. Hypopharynx 1.170 cT1 pN3 Poorly differentiated SCC
12. Hypopharynx 0.790 cT1 cN3 Poorly differentiated SCC
13. Supraglottic larynx 0.882 cT1 cN3 Poorly differentiated SCC
14. Parotis 0.908 cT1 cN3 Moderately differentiated carcinoma planocellulare
15. Neck soft tissueb 0.943 pT2 pN0 Hemangiosarcoma
16. Base of tonguea 2.1 T0NX NO sign of malignancy
SCC squamous cell carcinoma
aFine needle aspiration cytology of a neck nodal mass was false positive for cancer
bNeck mass was considered by cytology and by both imaging methods metastatic nodal conglomerate
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obtaining a better assessment of the PT in the HN re-
gion. Panendoscopy with imaging-directed biopsy to sus-
pected PT sites or to the most frequent sites of occult
tumour can detect CUP. If the metastatic nodes are in
the upper and/or middle cervical levels and non-invasive
diagnostic tools are negative for CUP, tonsillectomy
might be the diagnostic and therapeutic choice, espe-
cially in the case of SCC [27]. In our study, none cancer-
positive tonsillectomy cases were found after non-
invasive diagnostic tools failed to detect the CUP.
In the literature, several publications describe the effi-
cacy of FDG-PET/CT in detecting CUP with cervical
Fig. 5 Images obtained from a 54-year-old female illustrate a false positive interpretation error (arrows) on conventional MRI scans (a T1W, b T2W, c
CET1WFS). On the axial trace DW image (d, b-value: 1,000 s/mm2), a signal increase can be seen without diffusion restriction on the ADC map (e), which
measured 2.100 × 10−3 mm2/s in the radix linguae corresponding to inflammation and 0.834 × 10−3 mm2/s in the LN (f). CUP, SCC, stage TXN2bM0
Table 4 Therapies administered for clinically occult 36 PTs with neck node metastasis
Tumor sites RT RT+ ND CT CT + RND CRT CRT + ND MND Sum + Primary Tumor resection
Nasopharynx 3 3
Mesopharynx 1 2 3 1 tumor resection
Base of tongue 2b 2
Palatine tonsil 1 1 2 1 tonsillectomy
Hypopharynx 1 + 1 2
Larynx 1 1
Parotis 1 1 parotidectomy
Neck soft tissue 1 1 tumor resection
Lung 1 1 lobectomy
Breast 1 1
Colon / sigma 1 1
Final CUP 2 3a 1 4 7b 1++ 18
3 3 2 1 12 14 1 36
In one patient the lymph node cytology was false positive proven by the further examinations. One patient refused the treatment
CUP cancer of unknown primary, ND neck dissection, RND radical ND, MND modified ND, SND selective ND, RT radiotherapy, CT chemotherapy,
CRT chemoradiotherapy
a1 RND, 1 SND, 1 MND + patient refused RT
b1 MND other RND ++ wait and see follow up
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LN metastases [10, 28, 29]. The increased glycolysis of
malignant cells can be detected with PET using 18F-
labeled FDG, and FDG-PET was shown to change the
clinical management of one-third of CUP patients [30].
In our study, we found similar detection rates of pri-
mary sites when using 3T MPMRI (39.5 %) and PET-CT
(44.7 %). PET/CT showed higher sensitivity (Sv: 94.4 %)
but lower specificity (Sp: 65.0 %) in detecting the PT site
compared to 3T MPMRI (Sv: 88.2 %, Sp: 71.4 %).
DWMRI did not improve the sensitivity, but increased
the specificity of MPMRI.
Srinivasan et al. verified that DWI can also be success-
fully used on 3T machines. These authors reported a
mean ADC value of 1.101×10−3 mm2/s in the character-
isation of HNSCC [31, 32]. Studies have also evaluated
the influence of magnetic field strength on ADC values
and reported no statistically significant difference in HN
tumours between the ADC values at 1.5 and 3T [33, 34].
Moreover, ADC values are independent of magnetic field
strength [35].
In our patient group, the mean ADC value of histolog-
ically proven PTs was 0.892×10−3mm2/s. Inflammatory
tissue with a high fluid content can result in a signal in-
crease, not only in lower b-value images but also in high
b-value images (similar to tumorous tissue), because of
incomplete suppression of the signal (the so-called T2
shine through phenomenon). However, the increased
ADC value allows for differentiation between inflamma-
tion and tumour; in a case of suspected tumour on con-
ventional MR sequences, quantitative evaluation of ADC
(2.1×10−3mm2/s) could be used to determine the accur-
ate diagnosis of inflammation (Fig. 4).
SCC in the palatine tonsil can be challenging it is rarely
necrotic and typically shows a homogeneous appearance
similar to normal lymphoid tissue in the tonsil when
viewed using conventional MRI [36]. In our study, the lin-
gual tonsil was the most challenging site, often pitfalls in
our CUP evaluation. We evaluated 3 false positives beside
3 true positives with MPMRI and 5 false positives and 2
true positives with PET/CT in the base of tongue region.
Diffusion can also be restricted in non-tumorous lingual
tonsil tissue, and DWI by itself is thus not sufficient for
tumour differentiation in normal sized and -shaped lingual
tonsil. In the 3 false positive base of tongue cases DWI
demonstrated by the high signal intensity on high-b-value,
decreased signal intensity on the ADC map, and resulted
0.928, 0.741, 1.13×10−3mm2/s ADC values.
Detection of the primary cancer site before the start of
treatment is of great significance because this location
reduces unwanted side effects [37, 38]. In a previous
study, the 3-year survival rate of patients with detected
HN PTs was 100 % after selected treatment, as com-
pared to 58 % in patients with elected therapy for un-
known PT tumours [39].
Our cancer patients 32 received radiotherapy (66–70 Gy),
partly combined with chemotherapy (26 patients). In cases
of detected primary, 3D-conformal IMRT was applied due
to its better technical capacity, to reduce the dose delivered
to normal tissues because of its improved focus on the pre-
cision of target volumes.
The patients’ follow-up care included a follow-up visit
with the HN specialist every three months, an MRI exam-
ination every six months, and an annual PET/CT examin-
ation. In the past three and half years, only 3 patients (out
of 38) have died, 2 because of extended tumour spread,
one in the triple negative breast carcinoma, and one in the
lung adenocarcinoma, the third patient withT3N2b stage
palatine tonsil cancer because of vascular, myocardial at-
tack. There was no case in which the PT appeared after
radical therapy. About one year after CRT in 3 patients
appeared recurrent neck node metastases, in all the three
cases the initial N stage was N3.
Limitations
Our study, however, had some limitations. First, this was
a retrospective study covering only a 3.5-year period.
Second, the number of patients was small (n = 38), and
therefore the results and correlations should be inter-
preted with caution.
Conclusions
In cases with highly probable PT sites detected by either
MPMRI or FDG-PET/CT, imaging may provide clini-
cians with valuable information on where to obtain a
tissue sample.
Because conventional native sequences with DWI, 3T-
MPMRI and PET/CT were similarly accurate (Acc:
79.0 %) and had similar likelihood ratio (LR: 3.42, 3.03,
2.62) for detecting unknown PT sites, both imaging
methods may be used to determine the final diagnosis of
patients with CUP in the HN region. DWMRI by its in-
creased specificity (Sp: 77.8 %) and likelihood ratio (LR:
2.95) was shown to be capable of differentiating tumour
from non-tumorous tissue. Disadvantage of DWI is its
high sensitivity to the motion artefacts (5/38, 13.2 %).
The sensitivity of FDG-PET/CT (94.4 %) is higher than
MPMRI (88.2 %), and this statistical indicator in case of
finding CUP is more important, than the specificity of
the modalities.
Although MPMRI has the advantage of being radiation
free, but this is hardly a concern in this patient group as
most of the patients get radiation therapy.
While using PET/CT whole body information can be
obtained in one examination along with information
about metastases, and second malignancies.
MPMRI shows the local soft tissue status and the con-
nection of the primary tumor with the surrounding or-
gans more accurately.
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Summarizing the above, mentioned results, in case of
CUP PET/CT should be the first method of choice if it
is available.
After clinically proved positive PET/CT the additional
MPMRI can clarify the exact primary tumor stage, it can
be advantageous in clarifying the prognostic factors,
which is necessary in case of advanced tumor stage and
when surgery is under consideration.
In case low N stage is likely after the clinical examin-
ation and wait and see policy can be considered, MPMRI
is recommended, and in this case the significance the of
radiation free MPMRI is increasing.
In cases with PT-positive imaging results during CUP
evaluation, the next step should be panendoscopy with
biopsies.
For radiation therapies planning both imaging modal-
ities are effectively applicable.
The head and neck imaging is a challenging area which
needs strict protocols, special attention and well trained
specialists, radiologists and radiographers as well.
Additional file
Additional file 1: Table 5. Data collection. (XLSX 22 kb)
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